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ABSTRACT 23 
Purpose: Chronic obstructive pulmonary disease (COPD) is associated with altered metabolism 24 
and body composition that accompany poor outcomes. We aimed to determine whether metabolic 25 
derangements in COPD are associated with skeletal muscle deconditioning and/or physical 26 
inactivity, independent of pulmonary obstruction.  27 
Methods: We characterized serum metabolites associated with muscle oxidative capacity or 28 
physical activity in 44 COPD patients (FEV1=61±4%predicted) and 63 current and former smokers 29 
with normal spirometry (CON) (FEV1=93±2%predicted). Medial gastrocnemius oxidative 30 
capacity was assessed at rest from the recovery rate constant (k) of muscle oxygen consumption 31 
using near-infrared spectroscopy. Step counts and physical activity (average vector magnitude 32 
units (VMU)/min) were measured over 5-7 days using triaxial accelerometry. Untargeted prime 33 
and lipid metabolites were measured using liquid chromatography and mass spectrometry.  34 
Results: Muscle k (1.12±0.05 vs. 1.68±0.06min-1; P<0.0001; d=1.58) and VMU/min (170±26 vs. 35 
450±50 VMU/min; P=0.004; d=1.04) were lower in severe COPD (FEV1<50%predicted, n=14-36 
16) compared with CON (n=56-60). 129 prime metabolites and 470 lipids with known identity 37 
were quantified. Using sex as a covariate, lipidomics revealed 24 differentially expressed lipids 38 
(19 sphingomeylins) in COPD, consequent to a diminished sex difference of sphingomeylins in 39 
COPD (FDR<0.05; n=44). Total, and some individual, fatty acid concentrations were greater in 40 
severe COPD than CON (FDR<0.05; n=16; d=0.56-1.02). After adjusting for FEV1%predicted, 41 
we observed that grouped diacylglycerides (=-0.745; FDR=0.03) and triacylglycerides (=-42 
0.811; FDR=0.01) were negatively associated with muscle oxidative capacity, but not physical 43 
activity, in severe COPD (n=14). Conclusion: Strong negative associations relate impaired 44 
mitochondrial function to the accumulation of serum aclyglycerides in severe COPD. 45 
Key Words: metabolomics, mitochondria, physical activity, sphingomyelin, fatty acid  46 
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INTRODUCTION 47 
Chronic obstructive pulmonary disease (COPD) is associated with airway inflammation, mucus 48 
hypersecretion, and pulmonary emphysema; each contributing to expiratory flow limitation. 49 
Unifying symptoms of these heterogeneous phenotypes are dyspnea on exertion and exercise 50 
intolerance. Exercise intolerance and physical inactivity, not pulmonary obstruction, are the 51 
strongest predictors of mortality in COPD (1). Although no therapies beyond smoking cessation 52 
are yet proven to slow disease progression or reduce mortality, pulmonary rehabilitation - a 53 
multidisciplinary program that includes exercise training - is the most effective treatment in 54 
releveling symptoms, increasing quality of life, reducing hospitalizations and morbidity in COPD 55 
patients (2). A primary benefit of pulmonary rehabilitation in COPD is symptom relief and 56 
increased exercise tolerance, which are mediated by ameliorating skeletal muscle deficits in 57 
oxidative capacity, thereby delaying the onset of exercise-induced metabolic acidosis and reducing 58 
the ventilatory demands for a given activity (3). 59 
 60 
Several studies of serum metabolomics show metabolic dysregulation in COPD (4-6). Alterations 61 
in sphingolipid metabolism are common in COPD, suggesting a deficit in lipid metabolism that 62 
may contribute to smoking-induced lung damage through mitophagy-mediated necroptosis (7). 63 
Altered mitochondrial β-oxidation, tryptophan metabolism, carnitine/acylcarnitine, reduced 64 
polyunsaturated fatty acids and high oxidative stress are common findings following cigarette 65 
smoke exposure and in COPD metabolomic analyses (8). Furthermore, cigarette smoke exposure 66 
is associated with the accumulation of cytotoxic ceramides in lung epithelial cells and reduced 67 
mitochondrial respiration in skeletal muscle, resulting in insulin resistance and poor glucose 68 
tolerance (7, 9). 69 
 70 
Muscle deconditioning following physical inactivity is associated with a reduced fraction of 71 
whole-body ATP turnover that is derived from mitochondrial β-oxidation during rest or exercise 72 
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(10). Loss of mitochondrial oxidative capacity in skeletal muscle is, therefore, a primary variable 73 
implicated in mediating the association between hyperlipidemia and COPD. As both physical 74 
activity and oxidative capacity are negatively associated with COPD severity (11), this study 75 
aimed to determine whether lipid metabolite dysregulation in COPD was associated with muscle 76 
oxidative capacity and/or physical inactivity. We hypothesized that alteration of lipid metabolites 77 
in COPD would be associated with muscle oxidative capacity, independent of pulmonary function. 78 
 79 
METHODS 80 
Study population 81 
The population was drawn from the single-center Muscle Health Study, an ancillary study of 82 
COPDGene (ClinicalsTrials.gov Identifier NCT00608764). A total of 245 current or former 83 
smokers participated in the Muscle Health Study at The Lundquist Institute between 2013 and 84 
2016. Inclusion and exclusion criteria were determined by the COPDGene study design (12). 85 
Participants were non-Hispanic White or African American, aged 45–80 years, and all had 10 86 
pack-year smoking history. In addition, those with known or suspected cancer or recent (within 3 87 
months) hospitalization were excluded. Of the 245 subjects, 107 had serum samples collected for 88 
metabolomic investigation: 44 with COPD and 63 with normal spirometry acted as controls 89 
(CON). Participants gave written informed consent to participate as approved by the Institutional 90 
Review Board at The Lundquist Institute. Data of muscle oxidative capacity and pulmonary 91 
function from these participants has been previously reported (13). 92 
 93 
Additional methodological details are provided in supplemental digital content (SDC) (see 94 
Supplement for additional details of methods for clinical assessments, muscle oxidative capacity, 95 
prime metabolomics and lipidomics). 96 
 97 
Clinical assessments 98 
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As part of the COPDGene study protocol, clinical data collected included demographics, vital 99 
signs, medical and smoking history, and current medications. Spirometry was performed according 100 
to American Thoracic Society guidelines (14). Lung diffusing capacity for carbon monoxide 101 
(DLCO) was measured after post-bronchodilator spirometry assessment (15). Resting arterial 102 
oxygen saturation was measured using pulse oximetry (SpO2). 103 
 104 
Muscle oxidative capacity 105 
Oxidative capacity of the medial gastrocnemius muscle (k) was assessed using near-infrared 106 
spectroscopy (NIRS) as described previously (16). Prior work demonstrates, using direct 107 
measurements in single muscle fibers of varied biochemical phenotypes, that k is directly 108 
proportional to muscle oxidative capacity (17). The average k of two repeat measurements is 109 
reported. 110 
 111 
Physical activity  112 
At the end of the visit, participants received a triaxial accelerometer (DynaPort MoveMonitor, 113 
McRoberts BV, The Hague, the Netherlands) to assess number of steps per day and physical 114 
activity reported as vector magnitude units (VMU)/min. Activity measurements were considered 115 
complete if the participant maintained at least 15 hours of wearing time per day for at least 5 of 116 
the 7 days. 117 
 118 
Prime metabolomics and lipidomics  119 
Blood was collected from a peripheral vein using a serum separator tube (8.5 mL, BD Vacutainer) 120 
and the serum aliquoted (1 mL) and stored at -80C for subsequent analysis. Blood was collected 121 
typically ~3-4 hours after taking a usual breakfast. Serum samples were shipped to West Coast 122 
Metabolomics Center at the University of California for metabolomic analysis. 123 
 124 
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Statistics  125 
For general statistics, data are presented as mean ± SEM. Baseline subject characteristics, muscle 126 
oxidative capacity and physical activity were compared by ANOVA and Dunnett’s post hoc test 127 
using CON as the reference group (continuous variables) or chi2-test (categorical variables). 128 
Routine metabolomics data analysis was performed with MetaboAnlyst 3.0 129 
(www.metaboanalyst.ca). Differences in metabolite concentrations among groups were assessed 130 
by analysis of variance (ANOVA) and Fisher’s LSD post hoc test accounting for multiple 131 
comparisons using false discovery rate (FDR). Association between muscle oxidative capacity or 132 
physical activity and metabolite concentration was initially assessed using Spearman correlation 133 
stratified for GOLD class. Subsequently, lipid metabolites were categorized into 17 metabolite 134 
classes, grouped by their chemical properties, and partial correlation performed with adjustment 135 
for FEV1 %predicted.  136 
 137 
All comparisons were two-sided. Effect sizes are reported as Cohen’s d (d). For metabolite 138 
analyses, FDR ≤ 0.05 was considered statistically significant. For other analyses, P ≤ 0.05 was 139 
considered statistically significant.   140 
 141 
RESULTS 142 
Participant demographics and clinical characteristics 143 
The baseline characteristics of the study participants are presented in Table 1. Overall, 55% of the 144 
107 participants were female, 52% were African American and 48% were non-Hispanic White. 145 
COPD patients were significantly older than CON, less likely to be current smokers, and had a 146 
greater representation of non-Hispanic White participants. There were no significant differences 147 
between the groups in sex, weight, BMI, smoking history, diabetes or hypertension. By definition, 148 
FEV1/FVC and FEV1 %predicted were lower in COPD than CON. DLCO was significantly lower 149 
in COPD than CON, but there was no difference in resting SpO2 between the groups (Table 1). 150 
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Additional analyses were made on a sub-group comprised of only severe COPD (FEV1 < 50% 151 
predicted, n=16). This sub-population is shown separately in Table 1. Except for the degree of 152 
pulmonary obstruction (by definition) and a lower SpO2 than CON (not clinically significant: 153 
97.8±2.4 vs 96.1±0.7 %; d = 0.67), severe COPD patients had baseline characteristics that were 154 
similar to the whole COPD group (Table 1). 155 
 156 
Muscle oxidative capacity and physical activity 157 
Non-invasive measurement of the mV̇O2 recovery rate constant, k, was successful in 42 (95%) 158 
COPD and 56 (89%) CON participants. k was significantly lower in COPD than CON (1.32±0.07 159 
min-1 vs. 1.68±0.06 min-1; P < 0.0001; d = 0.81, Figure 1A), and lower still in the COPD patents 160 
with severe disease (FEV1 <50 %predicted) (1.12 ±0.05 min
-1; P < 0.0001 vs CON; n = 14; d = 161 
1.58) (Figure 1A). Forty-two (95%) COPD and 56 (89%) CON completed at least 5 days of triaxial 162 
accelerometer monitoring as designed (15 hours per day). Daily number of steps was not different 163 
between COPD and CON (5254±701 vs. 6188±442 steps/day, P = 0.375; d = 0.23) but was lower 164 
in severe COPD (3171±568 steps/day; P = 0.010 vs. CON; d = 1.04) (Figure 1B). Physical activity 165 
was not different between COPD and CON (353±43 vs. 450±50 VMU/min; P = 0.233; d = 0.30) 166 
but was lower in severe COPD (170±26 VMU/min; P = 0.004 vs. CON; d = 1.04) (Figure 1C).  167 
 168 
Sex differences in serum sphingomyelin were diminished in COPD patients  169 
Lipidomics analysis using sex as a covariate revealed 24 differentially expressed lipids between 170 
all COPD and CON (one-way ANOVA) (Figure 2A; FDR < 0.05; d = 0.36-1.31), of which 19 171 
were sphingomyelins. Post hoc analysis showed that this effect was driven by a significant 172 
difference between males and females in the CON group (see Table SDC 1, for a list of metabolites 173 
and differences). In CON, sphingomyelin concentrations were generally greater in females than 174 
males, and 38 sphingomyelin species were identified significantly greater in females than in males 175 
(Figure 2B; FDR < 0.05; d = 0.58-1.32; Table SDC 2, for a list of sphingomyelins that were 176 
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significantly different between males and females in CON). Conversely, in COPD, only 4 177 
sphingomyelins were significantly greater in females than males (Figure 2C; FDR < 0.05; d = 178 
1.00-1.35; see Table SDC 3, for a list of sphingomyelins that were significantly different between 179 
males and females in COPD). These data indicate that the anticipated differences in sphingomyelin 180 
concentrations between the sexes were diminished in COPD patients.  181 
 182 
Fatty acid metabolites were increased in severe COPD patients 183 
Prime metabolomics and lipidomics analysis identified 129 prime metabolites and 470 lipids with 184 
known identity in the serum of study participants. Metabolite concentrations were not significantly 185 
different between COPD and CON. However, several metabolites, predominantly fatty acids, were 186 
differentially expressed in severe COPD (FEV1 < 50 %predicted; n = 16) compared with CON. In 187 
lipidomics analysis, total fatty acid concentration was significantly greater in severe COPD than 188 
in CON (Figure 3A; P < 0.05; d = 1.02). This was predominantly due to 4 fatty acids that were 189 
significantly greater in severe COPD than in CON (Figure 3B; FDR < 0.05; d = 0.83-0.89). In the 190 
prime metabolites, the concentrations of 7 fatty acids were significantly greater in severe COPD 191 
than in CON (Figure 3C; FDR < 0.05; d = 0.59-1.02). 192 
 193 
Acylglycerides were negatively associated with muscle oxidative capacity in severe COPD  194 
Spearman correlation analysis was employed to identify whether metabolite concentrations were 195 
associated with the mV̇O2 recovery rate constant (k) and/or physical activity. All individual 196 
diacylglyceride (DG) and triacylglyceride (TG) metabolites had negative correlation with muscle 197 
oxidative capacity after adjusting for FEV1 %predicted (which incorporates adjustment for age, 198 
sex, race and height (18)). There were no significant associations between TG or DG with age, 199 
BMI, resting systolic or diastolic blood pressure, current smoking status, smoking history, FEV1 200 
%predicted, incidence of diabetes or hypertension, steps/day or VMU/min. Overall, 7 out of 8 DG 201 
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and 48 out of 102 TG were nominally negatively associated with muscle oxidative capacity in 202 
severe COPD (Figure 4A, P < 0.05; n = 14). 203 
 204 
Next, lipids were grouped into 17 classes based on their characteristics, and partial correlations 205 
were re-assessed. Following adjustment for FEV1 %predicted and correcting for FDR, we found 206 
that muscle oxidative capacity was negatively correlated with diacylglyceride concentration ( = 207 
-0.7447; FDR = 0.03) and triacylglyceride concentration ( = -0.8118; FDR = 0.01) in severe 208 
COPD patients (n = 14), but not in CON (n = 56). Neither daily steps nor physical activity were 209 
significantly associated in partial correlation with the concentrations of any metabolite group 210 
(Figure 4B). Adjustment of the partial correlation analysis using DLCO (a slightly stronger 211 
correlate of grouped metabolites than FEV1 %predicted), did not change the significant correlation 212 
between k and DG ( = -0.7544; FDR = 0.02) or TG ( = -0.8116; FDR = 0.01) in the severe 213 
COPD group (n = 14). Although there was no significant association between BMI and DG or TG, 214 
we also sought to adjust for BMI due to its potential association with hyperlipidemia. This 215 
adjustment did not substantively affect the correlation between k and TG ( = -0.7579; FDR = 216 
0.04), although the correlation was weakened between k and DG ( = -0.6746; FDR = 0.09). There 217 
remained no association between any lipid metabolite group and any measure of physical activity 218 
after adjustment for covariates. 219 
 220 
DISCUSSION 221 
In this study, we conducted both prime metabolomic and lipidomics analyses in COPD patients 222 
and controls, to identify whether serum metabolites were associated with physical activity and/or 223 
muscle mitochondrial oxidative capacity. We observed: 1) 24 lipids, including 19 sphingomyelins, 224 
were differentially expressed in COPD with sex as covariant; 2) sex-dependent differences in 225 
sphingomyelin concentration in controls were diminished in COPD patients; 3) severe COPD 226 
patients (n = 16) had elevated serum total fatty acids, centered on 8 individual fatty acid 227 
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metabolites; and, 4) serum concentrations of di- and tri-acylglycerides were negatively associated 228 
with muscle oxidative capacity, and not physical activity, in severe COPD (n = 14). Previous 229 
metabolomics studies of spirometrically-defined COPD reported dysregulation in several serum 230 
metabolite classes (4-6). Here we identify that skeletal muscle deconditioning in the form of 231 
reduced muscle oxidative capacity, common in COPD, may underlie metabolic dysregulation of 232 
di- and tri-acylglycerides in patients with severe pulmonary obstruction.  233 
 234 
Dysregulation of sphingolipid metabolism is common in patients with COPD. In an untargeted 235 
lipidomic analysis of sputum samples, Telenga et al. (19) demonstrated that sphingolipids, 236 
including several serum sphingomyelins, were significantly greater in smokers with COPD than 237 
those without COPD. Thirteen individual serum lipid metabolites, including one sphingomyelin, 238 
showed strong negative association with FEV1 and inflammation in sputum. Telenga et al. also 239 
found that two months of smoking cessation reduced concentration of 26 sphingomyelins in both 240 
groups (19). Others have demonstrated a significant negative association between sphingomyelin 241 
metabolites and emphysema from chest CT measurements (5) or COPD exacerbation severity (7).  242 
 243 
Consistent with studies of healthy subjects (20), our data showed greater serum sphingomyelin 244 
concentration in females than in males in our control group, which consisted of current or former 245 
smokers with normal spirometry. We found that this sex difference was diminished in all COPD 246 
patients, suggesting a sex-dependent alteration of sphingomyelin metabolism in COPD. 247 
Intracellular ceramide concentration is regulated by sphingolipid metabolism and is implicated in 248 
cigarette smoking induced mitophagy (7). Sphingolipid metabolism was also associated with 249 
emphysema progression in sub-phenotyping analysis (21). Whether the diminishing sex-250 
differences in circulating sphingomyelin metabolism underlie the more rapid progression of COPD 251 
observed in women than in men deserves further attention.  252 
 253 
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We identified that the serum concentration of total fatty acids, and some individual fatty acids, 254 
were significantly greater in severe COPD (n = 16) than in controls (n = 63). This observation was 255 
in contrast with a small study of COPD (including 10 patients with severe COPD) by Wada et al. 256 
where total free fatty acid concentration was significantly lower in COPD than in healthy controls 257 
(22). This discrepancy may reflect the disease stage of the subjects in each study; BMI in the severe 258 
COPD patients in the study of Wada et al. was significantly lower than controls, while there was 259 
no difference in BMI between groups in our study. 260 
 261 
The role of individual circulating fatty acids in the progression of pulmonary, cardiovascular or 262 
metabolic disease in COPD patients is not well studied. For example, increased dietary intake of 263 
fatty acids is associated with greater expiratory flow limitation in COPD patients, while dietary 264 
intake of pentadecylic acid may improve lung function in these patients (23). We found 7 265 
individual fatty acids in prime analysis and 4 in lipidomics that were greater in severe COPD, with 266 
3 individual fatty acids recapitulated in both analytic approaches (myristic acid, plamitoleic acid 267 
and heptadecanoic acid). Myristic acid potentiates palmitic acid-induced lipotoxicity, likely 268 
through mitochondria-related mechanisms (24). Similar to a previous investigation (25), we found 269 
that the monounsaturated fatty acid, palmitoleic acid, was greater in severe COPD; which is 270 
associated with greater high and low density lipoprotein cholesterol (26). On the other hand, lauric 271 
acid was also increased in severe COPD in our prime analysis, which is implicated in potentially 272 
beneficial effects on cholesterol, insulin resistance and inflammation. Given the low mitochondrial 273 
oxidative capacity we found in muscles of severe COPD patients (13), and the known greater odds 274 
of cardiometabolic disease in severe COPD, the differential effects on COPD or COPD 275 
progression of the individual fatty acids identified here deserve further study. 276 
 277 
Despite variability in the prevalence of hyperlipidemia, subclinical atherosclerosis occurs at a 278 
greater than expected prevalence in COPD, and is associated with more frequent exacerbations 279 
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(27). Regular physical activity and increased mitochondrial function are associated with lower 280 
blood lipids and triglycerides, and are protective of metabolic and cardiovascular disease (28). 281 
Therefore, identifying whether differences in physical activity and/or mitochondrial function 282 
underlie the observations of lipid metabolite dysregulation in COPD was a major thrust of this 283 
study. Overall, we did not find significant associations between lipid metabolites and either muscle 284 
oxidative capacity or physical activity when considering differences between all COPD patients 285 
and controls. However, there was a significant ceiling effect on these variables, and so we focused 286 
our analyses on severe disease (FEV1 < 50 %predicted). In severe COPD, there was a strong 287 
negative association between muscle oxidative capacity and serum di- or tri-acylglycerides ( 288 
ranged -0.75 to -0.81; n = 14). These associations remained even after adjusting for false discovery 289 
rate, and FEV1 or DLCO or BMI. It was striking that physical activity (either steps/day or 290 
VMU/min; n = 16) was not significantly associated any serum lipid metabolite or metabolite group 291 
investigated. This distinction is important because it implies that mitochondrial metabolic health, 292 
rather than physical activity per se, may be involved in lipid dysregulation in severe COPD. 293 
 294 
Support for this concept is found elsewhere in biology with, for example: a) no reduction in 295 
mortality in mice selectively bred for high lifelong energy expenditure, whereas rats selectively 296 
bred for endurance running capacity begets high muscle oxidative capacity and a ~40% increase 297 
in median lifespan (29); b) while high rates of physical activity are known to reduce all-cause 298 
mortality risk (30), the hazard ratio for mortality in 8,171 male veterans was reduced by ~50% 299 
when stratifying by exercise capacity compared with stratifying for physical activity (31); c) there 300 
was no survival benefit of increasing self-reported physical activity in longitudinal study of 1,270 301 
COPD patients with a median follow-up duration of 17 years (32). On the other hand, it is well 302 
established that exercise training, as part of a pulmonary rehabilitation program, increases muscle 303 
oxidative capacity (33), reduces 1-year hospital readmission (odds ratio vs. usual care = 0.44 (95% 304 
confidence interval 0.21 – 0.91), and potentially reduces 1-year mortality (odd ratio = 0.68 (0.28 305 
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– 1.67)) (2), without an impact on physical activity (34); d) changes in fat free mass and exercise 306 
capacity (but not physical activity) in COPD are also associated with rapid decline in health status 307 
(35).  308 
 309 
Metabolic syndrome is prevalent in COPD (36). Previous findings identified that an increase in 310 
circulating triglycerides is a major risk factor for 5-year mortality in COPD patients (37). 311 
Hypertriglyceridemia and systemic inflammation are independent predictors of elevated 312 
plasminogen activator inhibitor-1 in COPD, a major inhibitor of fibrinolysis, associated with 313 
thrombosis, obesity, insulin resistance, dyslipidemia, and premature aging; each prevalent in 314 
COPD (38). Intracellular accumulation of triglycerides and other fatty acids, promote endoplasmic 315 
reticulum stress, mitochondrial uncoupling and oxidative stress, which terminates in inflammation 316 
and cell death (39). Perivascular adipose accumulation seems to trigger atherosclerosis and 317 
hypertension, also prevalent in COPD. The association between circulating triglycerides and 318 
muscle mitochondrial oxidative capacity we identified in severe COPD provides a strong 319 
justification for the role of increasing physical fitness in reducing cardiovascular and metabolic 320 
risk in this patient population. Our proposal is that attempts to redress lipid metabolic deficits in 321 
COPD should not focus on simply diet or activity interventions, but specifically on obtaining the 322 
health-related benefits associated with increasing muscle (and other tissue) mitochondrial 323 
oxidative capacity. 324 
 325 
There are several limitations to this study. The number of subjects is low, particularly in the severe 326 
COPD group, which limited the statistical power to detect associations between individual lipid 327 
metabolites and muscle oxidative capacity or physical activity. Diet and circadian rhythm are 328 
known to regulate metabolism. Our serum samples were not collected with dietary control or at 329 
the same circadian time range, both of which could influence postprandial lipid profile and 330 
contribute to variation in metabolite concentrations. In addition, increased carbohydrate and fatty 331 
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acid intake are associated with worse pulmonary function (23). In attempt to mitigate this potential 332 
confounder, our findings remained after adjusting for FEV1 %predicted. We were not able to 333 
include measurements of adiposity or analysis of systemic markers of inflammation, which could 334 
have contributed to our understanding of lipid dysregulation. The measure of muscle oxidative 335 
capacity we used is non-invasive; nevertheless, it was successful in 92% of participants and we 336 
have demonstrated this method has strong reproducibility in COPD patients (16), while others 337 
have shown good association (r = 0.61-0.74) with muscle biopsy (40). 338 
 339 
In conclusion, we observed that 24 lipids, including 19 sphingomyelins, were increased in COPD 340 
with sex as covariant, and that sex-dependent differences in sphingomyelin concentration in 341 
controls were diminished in COPD patients. We also found that severe COPD patients had elevated 342 
serum total fatty acids, which centered on 8 individual fatty acid metabolites. These findings may 343 
in part underlie the more rapid progression of COPD observed in women than in men and the high 344 
prevalence of cardiovascular disease in COPD patients. Lipid dysregulation that was negatively 345 
associated with muscle oxidative capacity ( ranged -0.75 to -0.81; n = 14), and not physical 346 
activity (n = 16); a negative association which remained despite adjustment for FEV1 %predicted, 347 
DLCO or BMI. The strong negative association we identified between di- or tri-acylglycerides and 348 
muscle oxidative capacity, suggests that impaired mitochondrial function may play a role in the 349 
accumulation of serum aclyglycerides in severe COPD, and provides a strong rationale for 350 
targeting mitochondrial deficits by exercise training, or other means, to improve outcomes in this 351 
patient population. 352 
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FIGURE LEGENDS 483 
Figure 1. Muscle oxidative capacity and physical activity is reduced in severe COPD 484 
patients compared with controls (CON). A) Muscle oxygen consumption recovery rate 485 
constant (k, min-1), which is linearly proportional to muscle oxidative capacity (CON n=56; ALL 486 
COPD n=42; severe COPD n=14). B) Daily steps (CON n=56; ALL COPD n=42; severe COPD 487 
n=16). C) Average daily VMU/min (CON n=56; ALL COPD n=42; severe COPD n=16). 488 
 489 
Figure 2. The sex difference of serum sphingomyelin concentration was diminished in 490 
COPD patients compared with controls (CON). (A) ANOVA of lipidomics of COPD patients 491 
(n=44) and CON (n=63) with sex as a covariant. Filled red circles indicate metabolites with 492 
significant difference among groups. (B) Comparison of sphingomyelin (SM) concentration 493 
between male and female CON subjects (n=63). (C) Comparison of sphingomyelin (SM) 494 
concentration between male and female COPD patients (n=44). Filled pink circles indicate 495 
metabolites with significant difference between the sexes. Data were corrected for false 496 
discovery rate (FDR).  497 
 498 
Figure 3. Fatty acids were increased in severe COPD patients compared with controls. 499 
Lipid metabolites in severe COPD patients (FEV1 < 50% predicted, open symbols/open bars) 500 
compared with CON (filled symbols/filled bars). (A) Total fatty acids were significantly greater 501 
in severe COPD patients compared with CON in lipidomics analysis. (B) Four fatty individual 502 
acids were identified as significantly greater in severe COPD patients in lipidomics analysis. (C) 503 
Seven fatty acids were identified as significantly greater in severe COPD patients in prime 504 
metabolite analysis. Data were corrected for false discovery rate (FDR): * FDR<0.05; ** 505 
FDR<0.01; *** FDR< 0.005; **** FDR<0.001; CON n=63; severe COPD n=16.  506 
 507 
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Figure 4. Diacylglyceride (DG) and triacylglyceride (TG) classes of lipid metabolites were 508 
correlated with muscle oxidative capacity in severe COPD. (A) Spearman correlation analysis 509 
of 470 individual lipid metabolites with muscle oxidative capacity in severe COPD. Individual 510 
metabolites were placed into classes based on their characteristics, shown in panel B. (B) Partial 511 
correlation of grouped lipid metabolites with muscle oxidative capacity, daily steps and physical 512 
activity (VMU/min). Data were adjusted for FEV1 % predicated and corrected for FDR. 513 
Statistically significant associations were identified for DG and TG classes (panel B). DG and 514 
TG regions within the individual metabolite data are highlighted in panel A by horizontal dash. * 515 
FDR<0.05. Severe COPD n=14-16. 516 
 517 
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Table 1. Participant characteristics. 
  Unit CON 
ALL  
COPD 
Severe 
COPD 
p value 
ALL COPD 
vs CON 
p value 
Severe COPD 
vs CON 
Number of Subjects n 63 44 16 - - 
GOLD 1/2/3/4 n 0 / 0 / 0 / 0 14 / 14 / 9 / 7 9 / 7 - - 
Age years 61.2 ± 1.3 65.6 ± 1.4 66.6 ± 1.6 0.039 0.086 
Sex, M / F n 29 / 34 21 / 23 6 / 10 0.981 0.786 
Race, NHW / AA n 21 / 42 30 / 14 13 / 3 <0.0001 <0.001 
Weight kg 85.3 ± 2.7 79.2 ± 2.6 78.1 ± 4.7 0.209 0.330 
BMI kg/m2 29.8 ± 0.9 28.2 ± 0.9 29.2 ± 1.8 0.405 0.941 
Smoking history pack-years 39.2 ± 2. 6 46.5 ± 3.6 47.0 ± 6.4 0.187 0.372 
Smoking duration years 35.6 ± 1.3 37.2 ± 1.5 35.4 ± 2.7 0.656 0.997 
Current smoker n (%) 34 (54) 13 (30) 3 (13) 0.020 0.018 
FEV1/FVC % 79.6 ± 0.7 52.5 ± 2.4 35.8 ± 3.3 <0.0001 <0.0001 
FEV1 % predicted % 93.4 ± 2.2 61.4 ± 4.1 31.6 ± 2.9 <0.0001 <0.0001 
DLCO mL/min/mmHg 75.9 ± 2.2 61.3 ± 3.6 41.8 ± 3.9 0.001 <0.0001 
Diabetes n (%) 13 (21) 4 (9) 1 (6) 0.181 0.265 
Hypertension n (%) 36 (57) 21 (48) 8 (50) 0.557 0.844 
SpO2 % 97.8 ± 2.4 97.3 ± 2.0 96.1 ± 0.7 0.421 0.015 
GOLD, global initiative for obstructive lung disease spirometric classification (1, Mild; 2, Moderate; 3, Severe; 
4, Very-severe); NHW, non-Hispanic White; AA, African American; BMI, body mass index; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide; SpO2, 
oxyhemoglobin saturation by pulse oximetry. Spirometric variables are post -bronchodilator values. 
 
